Derrick Fox, MD
Neurology · Columbia, MDNPI 1336403237
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,688 of the $2,362 with a category attached, or 71.4%. Argenx US, Inc. accounts for 74.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $1,825 and has fallen 85.0% since, to $273 in 2025.
Across 25 payments — averaging $94.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$2K
- AstraZeneca$239
- AbbVie$170
- Johnson & Johnson$51
- Amgen$44
- Lundbeck LLC$23
- plus $87 from 4 others
Across 3 payments — averaging $9223.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$28K
What the payments were for
- Consulting fees$1,68871%
- Food & beverage$67529%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 3 | $1,749 |
| AstraZeneca(2 entities) | 6 | $239 |
| AbbVie | 7 | $170 |
| Johnson & Johnson | 2 | $51 |
| Amgen | 2 | $44 |
| Lundbeck LLC | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Livanova USA, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
How this compares
$2,362 in reported general payments places this provider in the 55th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 22 | $313,511 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 13 | $3,660 |
| Pyridostigmine Bromide | 36 | $3,151 |
| Dalfampridine ErDalfampridine | 20 | $2,669 |
| Mycophenolate Mofetil | 22 | $1,977 |
| Riluzole | 14 | $1,213 |
| Gabapentin | 53 | $535 |
| Teriflunomide | 12 | $489 |
| Duloxetine Hcl | 11 | $440 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 24 | $423 |
| Baclofen | 22 | $190 |
| Cyclobenzaprine Hcl | 16 | $167 |
| Prednisone | 13 | $78 |
| Donepezil Hcl | 11 | $19 |
Paid to pharmacies, not to this prescriber.
Other neurology in Columbia
- Daniel BeckerLutherville$1.6M
- Sangjin OhGlen Burnie$1.5M
- Pavel KleinBethesda$709K
- Ruwani GunawardaneFulton$479K
- Michael PolydefkisBaltimore$371K
- David CornblathLutherville$345K
- Shiv SaidhaBaltimore$298K
- Santiago Mazuera MesiaBaltimore$258K
- Bruce RabinLutherville$228K
- Thomas CrawfordBaltimore$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.